MedPath

Clinical Trial News

Collagenase Clostridium Histolyticum Shows Promise for Ventral Curvature in Peyronie's Disease

  • Interim data from a phase 4 retrospective study suggests that collagenase clostridium histolyticum (CCH) is effective for Peyronie's disease with ventral curvature.
  • The study reported an average reduction of 45.4% in ventral curvature after CCH treatment, with 68.8% of patients showing at least a 30% improvement.
  • Treatment-related adverse events were consistent with those seen in general CCH use, and no serious adverse events like urethral injury were reported.
  • These real-world data support the safety and efficacy of CCH for ventral penile curvatures, expanding its potential application in Peyronie's disease.

Low Blood S-methyl-5-thioadenosine Linked to Postoperative Cognitive Decline

  • A recent study reveals that low levels of S-methyl-5-thioadenosine (MTA) in the blood are associated with delayed neurocognitive recovery (dNCR) following surgery in elderly patients.
  • The research indicates that anesthesia and surgery can lead to a decrease in MTA levels, potentially contributing to postoperative cognitive dysfunction.
  • Supplementation with MTA or its precursor methionine in animal models showed promise in mitigating cognitive impairment after surgical procedures.
  • These findings suggest that monitoring and potentially modulating MTA levels could be a therapeutic strategy to reduce postoperative cognitive issues.

Study on the Characteristics of Non-targeted Metabolomics and EEG of Delayed Neurocognitive Recovery in Elderly Patients

NCT05105451Active, Not Recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Posted 5/22/2021

Foresee's Linvemastat Shows Promising Safety Profile in Phase 1 Trial

  • Foresee Pharmaceuticals' linvemastat (FP-020), a novel oral MMP-12 inhibitor, demonstrates a favorable safety and tolerability profile in a Phase 1 clinical trial.
  • The Phase 1 study evaluated single and multiple ascending doses of linvemastat in healthy volunteers, with no serious adverse events reported.
  • Preliminary data supports further evaluation of linvemastat in Phase 2 trials for severe asthma, COPD, and inflammatory bowel diseases, planned for 2025.
  • Linvemastat's superior potency and pharmacokinetic properties position it as a potential best-in-class treatment for immune-fibrotic diseases.

Lung Cancer Research Highlights Time Toxicity, Air Quality Impact, and Palliative Care

  • A study quantified time toxicity in lung cancer clinical trials, revealing a significant increase in time demands on patients from 2005-2024.
  • Analysis of global data showed air pollution is an increasing risk factor for lung cancer mortality, especially in populous countries like India and China.
  • Research indicates that early palliative care for metastatic NSCLC patients leads to longer hospice stays and reduced aggressive end-of-life care.
  • The findings emphasize the need for streamlined trial protocols, stricter air quality policies, and proactive integration of palliative care in lung cancer treatment.

Philadelphia Hospitals Pioneer New Strategy for Treating 'Tranq Dope' Withdrawal

  • Philadelphia hospitals are testing a novel approach to manage withdrawal from 'tranq dope,' a combination of fentanyl and xylazine, which presents more severe symptoms than heroin withdrawal.
  • The new treatment strategy involves using short-acting opioids like oxycodone or hydromorphone, combined with low-dose buprenorphine, ketamine and adjunctive therapies.
  • This innovative approach has significantly reduced patient-directed discharges from hospitals, decreasing from 10% to under 4%, and has halved the severity of withdrawal symptoms.
  • The strategy addresses the challenges posed by tranq dope, where traditional treatments like buprenorphine alone often lead to precipitated withdrawal and ineffective symptom control.

NeoGASTRIC Trial Assesses Feeding Methods for Premature Infants

  • The NeoGASTRIC trial is evaluating whether routine measurement of gastric residual volumes affects the time it takes premature babies to reach full feeding volumes.
  • The study aims to recruit over 7,000 premature infants across the UK and Australia by 2026 to assess optimal feeding strategies.
  • Hinchingbrooke Hospital and Peterborough City Hospital are participating in the trial, contributing to improved neonatal care practices.
  • The research is funded by the National Institute for Health and Care Research (NIHR) and coordinated by the University of Oxford and Monash University.

Alzheimer's Research Funding Sees Monumental Increase Following Congressional Action

  • Funding for Alzheimer's research has surged from $562 million in 2014 to $3.8 billion, marking a significant increase in efforts to combat the disease.
  • The National Alzheimer's Project Act (NAPA), authored in 2011, established a national plan to address Alzheimer's, setting goals for prevention and treatment.
  • Recent bills to renew the U.S. commitment to addressing Alzheimer's have been passed by Congress and signed into law, ensuring continued focus on the disease.
  • Patients are benefiting from new FDA-approved treatments that slow the progression of Alzheimer's in its earliest stages, offering hope and improved quality of life.

FDA Halts Novavax's Combined COVID-Flu Vaccine Trial After Adverse Event

• The FDA has placed a clinical hold on Novavax's combined COVID-19 and flu vaccine program following a report of motor neuropathy in a Phase 2 trial participant. • Novavax is working to provide the FDA with the necessary information to resolve the hold, though the company states causality has not been established. • The clinical hold delays the development of Novavax's combined vaccine candidate, while Moderna is ahead with positive Phase 3 data for its own combined vaccine. • Novavax has launched its latest coronavirus vaccine for the current season, available in more locations and in a prefilled syringe, potentially boosting its market presence.

Antifibrotic Therapy Plus Chemotherapy Reduces Breast Cancer Recurrence in Phase 2 Trial

• A Phase 2 clinical trial demonstrated that the MeCo Score can predict the likelihood of relapse in early-stage breast cancer patients. • Patients with high MeCo Scores who received nintedanib plus chemotherapy experienced a 62% reduction in recurrence risk compared to chemotherapy alone. • The MeCo Score shows potential as a predictive biomarker for antifibrotic therapy, representing a new approach to fighting breast cancer. • A larger trial is planned to confirm these findings, potentially leading to a cost-effective, targeted therapy for breast cancer.

Strategies to Address Patient Fears Regarding JAK Inhibitor Safety Identified

  • A recent study highlights the importance of clear communication and patient education to address concerns about JAK inhibitor safety in dermatology.
  • The research suggests that using simple language, providing educational resources, and sharing personal anecdotes can alleviate patient anxiety.
  • Findings indicate that JAK inhibitors may pose fewer safety concerns for younger, healthier patients with dermatologic conditions compared to older patients with comorbidities.
  • Healthcare providers are encouraged to tailor educational efforts to individual patient needs to enhance outcomes and ensure adherence to JAK inhibitor therapy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.